Liquid Biopsy in 2026: Galleri, Shield, and the Multi-Cancer Screening Era
By Dr. Sarah Mitchell, Respiratory Equipment Specialist & Wellness Editor · Published 2026-08-14 · 8 min read
A single blood draw now screens for 50+ cancers with rising specificity. What Galleri, Shield, and CancerSEEK actually detect — and their limits.
The Idea, Finally Working
Circulating tumor DNA methylation patterns let a single blood test detect signals from dozens of cancer types.
2026 Landscape
- Galleri (Grail) — 50+ cancer signal, ~99.5% specificity, real-world PATHFINDER 2 data pending.
- Shield (Guardant) — FDA approved for colorectal cancer screening in average-risk adults 45+.
- CancerSEEK / Freenome — pancreatic, ovarian, and colorectal focus.
Interpret With a Clinician
A positive signal triggers a defined diagnostic workup, not panic. A negative result does not replace mammograms, colonoscopy, or low-dose CT for lung cancer screening.
---
Round Out Your Home Health Setup
Pair the latest wellness protocols with clinical-grade monitoring. Browse portable oxygen concentrators, CPAP machines, and respiratory accessories — or call our respiratory therapists at (877) 699-4365 for a free consult.